New hope for slowing scarring kidney disease
Disease control
Recruiting now
This study is testing whether an investigational drug called praliciguat can help control focal segmental glomerulosclerosis (FSGS), a disease that causes scarring in the kidneys. About 60 adults with confirmed FSGS will receive either the drug or a placebo for 24 weeks, followed…
Phase: PHASE2 • Sponsor: Akebia Therapeutics • Aim: Disease control
Last updated Mar 16, 2026 15:25 UTC